

**Amendments to the Claims** are reflected in the listing of the claims which begins on page 2 of this paper.

**Remarks** begin on page 6 of this paper.

**Listing of the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-21 (cancelled)

Claim 22 (currently amended): An isolated polypeptide having at least 80% sequence identity to:

- ①
- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
  - (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
  - (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;  
or
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.


Claim 23 (currently amended): The isolated polypeptide of Claim 22 having at least 85% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 24 (currently amended): The isolated polypeptide of Claim 22 having at least 90% sequence identity to:

- 
- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
  - (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
  - (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 25 (currently amended): The isolated polypeptide having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 26 (currently amended): The isolated polypeptide of Claim 22 having at least 99% sequence identity to:

- 9
- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
  - (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
  - (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 27 (previously added): An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or

- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 28 (currently amended): [The] An isolated polypeptide [of Claim 27] comprising the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83).

Claim 29 (currently amended): [The] An isolated polypeptide [of Claim 27] comprising the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide.

Claim 30 (previously added): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83).

Claim 31 (previously added): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide.

Claim 32 (currently amended): [The] An isolated polypeptide [of claim 27] comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 33 (previously added): A chimeric polypeptide comprising a polypeptide according to Claim 22 fused to a heterologous polypeptide.

Claim 34 (previously added): The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Claim 35 (New): The isolated polypeptide of claim 28, comprising a transmembrane domain at residues about 380 to about 409 of SEQ ID NO:83.